Form 4 AI
Back to all filings

Form 4 · Filed Jun 8, 2026, 10:01 PM UTC

BBIO/BridgeBio Pharma, Inc.

Kumar Neil — Chief Executive Officer

AI Thesis

A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.

Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.

Transactions

14 rows
DateCodeDirectionSharesPriceValueOwned after
Jun 5, 2026Ssell7,147$67$480,271528,539
Jun 5, 2026Ssell8,437$68$572,744520,102
Jun 5, 2026Ssell4,416$69$304,524515,686
Jun 5, 2026Ssell7,148$67$480,3384,331,299
Jun 5, 2026Ssell8,437$68$572,7444,322,862
Jun 5, 2026Ssell4,415$69$304,4554,318,447
Jun 4, 2026Ssell15,921$68$1,078,4524,338,897
Jun 4, 2026Ssell2,200$66$144,584553,486
Jun 4, 2026Ssell450$68$30,7214,338,447
Jun 4, 2026Ssell1,429$67$95,347552,057
Jun 4, 2026Ssell15,921$68$1,078,454536,136
Jun 4, 2026Ssell450$68$30,721535,686
Jun 4, 2026Ssell2,200$66$144,5844,356,247
Jun 4, 2026Ssell1,429$67$95,3474,354,818

Source: SEC EDGAR raw filing ↗ · Accession 0001470831-26-000523